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Background: The aim of this study was to investigate the variation of platelet-activating factor acetylhydrolase
(PAF-AH) in patients with various stages of hepatitis B infection and evaluate the association between PAF-AH
activity and chronic severe hepatitis B (CSHB) and mortality in patients with hepatitis B.
Methods: Serum PAF-AH activity was measured in 216 patients with hepatitis B and in 152 healthy controls using an
automatic biochemical analysis system. Spearman correlation was used to investigate the correlation between PAF-AH
activity and other biochemical indicators. The receiver operating characteristic (ROC) curve and multivariable logistic
regression analysis were used to evaluate the ability of PAF-AH activity to predict CSHB and mortality in patients with
hepatitis B.
Results: The PAF-AH activities in patients with CSHB (1320 ± 481 U/L) were significantly higher than those in
healthy controls and in other hepatitis B groups (all P < 0.01). In patients with hepatitis B, PAF-AH activity correlated
with total bilirubin (r = 0.633), total bile acid (r = 0.559), aspartate aminotransferase (r = 0.332), apolipoprotein B
(r = 0.348), high-density lipoprotein cholesterol (r = −0.493), and apolipoprotein AI (r = −0.530). The areas under the
ROC curves for the ability of PAF-AH activity to predict CSHB and mortality in patients with hepatitis B were 0.881
(95% confidence interval (CI): 0.824–0.937, P < 0.001) and 0.757 (95% CI: 0.677–0.837, P < 0.001), respectively.
Multivariate logistic regression analysis showed PAF-AH activity to be an independent factor predicting CSHB with
an odds ratio of 1.003 (95% CI: 1.002–1.005, P < 0.001).
Conclusion: Elevated PAF-AH in patients with hepatitis B was significantly associated with liver damage. Thus,
serum PAF-AH could be used as a novel indicator for predicting CSHB and mortality in patients with hepatitis B.
Further, PAF-AH activity was an independent factor predicting CSHB.
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Platelet-activating factor acetylhydrolase (PAF-AH) is a
Ca2+-independent catalyst of serine-dependent phospholipid
hydrolysis and belongs to the superfamily of phospholipase
A2 [1]. Also known as lipoprotein-associated phospholipase
A2 (Lp-PLA2), the plasma PAF-AH is a single 45-kilodalton
polypeptide composed of 441 amino acids encoded by the
PLA2G7 gene [2]. Because PAF-AH hydrolyzes platelet-
activating factor (PAF) and oxidizes phospholipids with a
modified short fatty acyl chain esterified at the sn-2 position
[3], PAF-AH plays an important role in human diseases
such as severe anaphylaxis [4], rheumatic diseases [5], acute* Correspondence: chenyu_zyyy@163.com
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unless otherwise stated.respiratory distress syndrome [6], necrotizing enterocolitis
[7], and atherosclerosis [8]. Previous epidemiologic studies
demonstrated that increased PAF-AH activity had a prog-
nostic value and was associated with a high risk of future
coronary and cerebrovascular events [9,10]. Additionally,
Kamisako et al. reported increased PAF-AH activity in pa-
tients with hyperbilirubinemic hepatobiliary disease [11].
However, to our knowledge, the role of serum PAF-AH in
hepatitis B has not yet been well defined. More importantly,
whether serum PAF-AH activities are associated with differ-
ent disease states of hepatitis B virus (HBV) infection such
as acute hepatitis B (AHB), chronic hepatitis B (CHB), and
chronic severe hepatitis B (CSHB) remains unknown. Thus,
in the present study, we aim to determine the activity of
serum PAF-AH in patients with various stages of hepatitisd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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A total of 216 hepatitis B patients, including 155 male and
61 female patients aged 13–82 (45.1 ± 13.4) years from the
Department of Infectious Disease, The First Affiliated
Hospital, School of Medicine, Zhejiang University, China,
were enrolled in our prospective study. Of these patients,
23 were diagnosed with acute hepatitis B (AHB), 67 with
chronic hepatitis B (CHB), 49 with chronic severe hepatitis
B (CSHB), and 77 with liver cirrhosis (LC). All patients
were diagnosed according to the criteria of the 2000 Xi’an
viral hepatitis management scheme [12]. The standardized
diagnosis of AHB, CHB, and CSHB has been previously
described in detail [13-15]. The model for end-stage liver
disease (MELD) score, calculated from the patient’s serum
total bilirubin (TBIL), creatinine level, and international
normalized ratio (INR) of prothrombin time, was used to
quantify the severity of liver disease [16]. A total of 152
healthy control patients with HBsAg negativity and nor-
mal liver and renal function and blood lipid levels at their
annual health examination at the healthcare center of The
First Affiliated Hospital of Zhejiang University were also
recruited. The control group comprised 102 male and 50
female patients aged 17–78 (46.0 ± 12.9) years. Patients
with a concurrent infection of hepatitis C virus (HCV),
hepatitis D virus, hepatitis G virus, and/or human im-
munodeficiency virus and any autoimmune liver disease
were excluded. There were no statistically significant dif-
ferences in gender and age distribution between the case
and control groups (both P > 0.05).
Ethics statement
This study was approved by the Ethics Committee of the
First Affiliated Hospital of College of Medicine at Zhejiang
University in China and was performed in accordance
with the Helsinki Declaration. All participants provided
written informed consent. For participants under 18 years
of age, oral informed consent was obtained from the par-
ticipants, and written informed consent was signed by
their parents.
Specimen collection
All specimens for blood indicators and PAF-AH activ-
ity measurements were collected by venipuncture into
5-mL drying Vacuette vacutainers (Greiner Bio-One
GmbH, Kremsmunster, Austria) in the morning after a
12 h fast on the second day after admission. The sam-
ples were sent to the laboratory, and serum was isolated
by centrifugation (10 min, 3000 × g) and preserved
at −80°C.Laboratory techniques
Biochemical indicators of liver function, such as alanine
aminotransferase (ALT), aspartate aminotransferase (AST),
total bilirubin (TBIL), cholinesterase (ChE), triglyceride
(TG), total cholesterol (Tch), low-density lipoprotein chol-
esterol (LDL-c), high-density lipoprotein cholesterol (HDL-
c), apolipoprotein AI (apoAI), apolipoprotein B (apoB),
glucose (Glu), and total bile acid (TBA), were assessed on a
Hitachi 7600 automatic biochemical analyzer (Hitachi Ltd.,
Tokyo, Japan) using reagents from Roche Diagnostics
(Roche Diagnostics GmbH, Mannheim, Germany) for ALT,
AST, TBIL, ChE, TG, and Tch measurements and reagents
from SSUF (SSUF Ltd., Shanghai, China) for LDL-c, HDL-
c, apoAI, apoB, and TBA measurements. PAF-AH activity
was measured by a previously described spectrophotomet-
ric assay using the Azwell Auto PAF-AH kit (Azwell Inc.,
Osaka, Japan). We used a combination of 3-[(3- cholamido-
propyl) dimethylammonio]-1-propanesulfonate (CHAPS)
and sodium 1-nonane sulfonate to avoid measuring
nonspecific esterase activity in our assay [17]. In brief,
PAF-AH hydrolyzes the substrate 1-myristoyl-2-(4-
nitrophenylsuccinyl) phosphatidylcholine at the sn-2
position, producing 4-nitrophenyl succinate, which is im-
mediately degraded to 4-nitrophenol and subsequently
measured spectrophotometrically at 405 nm at room
temperature. The enzymatic activity was expressed as IU/L.Statistical analysis
Statistical analysis was performed using SPSS software ver-
sion 13.0 (SPSS Inc., Chicago, IL, USA). Data are pre-
sented as mean ± SD, and categorical data as percentages.
For continuous variables, the differences between two
groups were assessed with the independent samples t-test
or the Mann–Whitney U test as appropriate. Multiple
comparisons were performed by one-way analysis of vari-
ance (ANOVA) or Kruskal-Wallis H tests. Categorical vari-
ables were analyzed using the chi-square test. Spearman’s
rank correlation test was used in correlation analysis. For
the univariate and multivariate analyses to identify inde-
pendent predictors, the measurements for PAF-AH activ-
ity, biochemical parameters, and hematological parameters
were presented as quartile ranks, with the lowest quartile
being used as the reference category. A receiver operating
characteristic (ROC) curve was generated and the area
under the curve (AUC) was calculated to identify the best
PAF-AH activity and/or MELD score for predicting CSHB
and mortality in patients with HBV infection. Stepwise re-
gression was performed to determine factors associated
with the incidence of CSHB. A multivariable logistic re-
gression analysis was used to evaluate PAF-AH activity and
the MELD score as predictors of CSHB by adjusting for
gender, LDL-c, and TBIL in the model. Statistical signifi-
cance was defined at P < 0.05.
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Detection of PAF-AH in patients with various clinical
stages of hepatitis B
In this study, 216 patients with hepatitis B and 152 healthy
control patients were enrolled as study participants. The
clinical characteristics of the patients are listed in Table 1.
The levels of ALT, AST, TBIL, CHE, TG, Tch, LDL-c,
HDL-c, apoA I, apoB, and TBA were statistically different
between each of the AHB, CHB, LC, and CSHB groups
and the healthy control group (all P < 0.05). The MELD
score and mortality were statistically different among the
four hepatitis B groups (all P < 0.05). The PAF-AH activity
was 820 ± 446 U/L in the 216 patients with hepatitis B,
significantly higher than that measured in healthy con-
trols, 450 ± 125 U/L (P < 0.01). The PAF-AH activities in
the AHB, CHB, LC, and CSHB groups were all signifi-
cantly higher than in control patients (all P < 0.05, Table 1).
Moreover, the PAF-AH activities in patients with CSHB
were significantly higher than those in patients with AHB,
CHB, and LC by the Mann–Whitney U test (all P < 0.001).
Correlation analysis between PAF-AH activity and other
laboratory indexes
Spearman correlation was employed to determine the cor-
relation between PAF-AH activity and other laboratory in-
dexes. We found that in hepatitis B–positive patients,Table 1 Clinical characteristics of enrolled participants
Variable Control (152) AHB (23) C
Female/male 50/102 12/11
Age (year) 45.1 ± 13.4 40.2 ± 14.9* 39
BMI (kg/m2) 22.9 ± 2.9 23.1 ± 2.8 2
TBIL (μmol/L) 13.1 ± 4.4 126.9 ± 108.5* 58
TBA (μmol/L) 3 ± 2 133 ± 86* 4
ALT (U/L) 19 ± 9 1289 ± 590* 40
AST (U/L) 19 ± 6 516 ± 398* 19
ChE (U/L) 8364 ± 1521 6003 ± 2012* 688
TG (mmol/L) 0.95 ± 0.33 1.95 ± 0.97* 1.4
Tch (mmol/L) 4.17 ± 0.58 3.46 ± 0.71* 3.6
HDL-c (mmol/L) 1.33 ± 0.24 0.42 ± 0.41* 0.8
LDL-c (mmol/L) 2.41 ± 0.47 1.46 ± 0.94* 1.9
apoAI (g/L) 1.18 ± 0.25 0.61 ± 0.35* 0.9
apoB (g/L) 0.69 ± 0.15 0.87 ± 0.27* 0.7
Cr (μmol/L) 71 ± 13 99 ± 156*
Glu (mmol/L) 4.76 ± 0.41 4.79 ± 0.81 4.
PT (s) - 12.7 ± 1.48 12
PAF-AH (U/L) 450 ± 125 872 ± 355* 61
MELD score - 11.9 ± 5.9
Mortality (yes/no) - 0/23
AHB: acute hepatitis B; CHB, chronic hepatitis B; LC, liver cirrhosis; CSHB, chronic sev
P-value: comparison among these five groups. #comparison among these four grouPAF-AH activity correlated positively with TBIL, TBA,
ALT, AST, TG, and apoB (Spearman correlation coeffi-
cients [r-values] = 0.633, 0.559, 0.176, 0.332, 0.276, and
0.348, respectively; all P < 0.05), correlated negatively with
ChE, HDL-c, and apoAI (r = −0.273, −0.493, and −0.530,
respectively; all P < 0.05), and did not correlate with Glu,
body mass index (BMI), Tch, or LDL-c levels (all P > 0.05).
Both TBIL and TBA levels were very significant correlated
with serum PAF-AH activity in hepatitis B patients (r-
values greater than 0.5, Figure 1). In contrast, in healthy
controls, PAF-AH activity correlated positively with TBIL,
ALT, ChE, TG, Tch, LDL-c, and apoB (r = 0.251, 0.244,
0.209, 0.200, 0.338, 0.416, and 0.436, respectively; all P <
0.05), correlated negatively with HDL-c (r = −0.176, P <
0.05), and did not correlate with Glu, BMI, TBA, AST, and
apoAI levels (all P > 0.05).
Association of PAF-AH with CSHB and 3-month mortality
in HBV-infected patients
To explore the association of PAF-AH with CSHB and
with mortality, the 216 patients with hepatitis B were di-
vided into four groups according to their PAF-AH activity
percentiles (group 1: PAF-AH >1053 U/L; group 2: 709–
1053 U/L; group 3: 477–708 U/L; group 4: <477 U/L). The
prevalence of CSHB was calculated by dividing the num-
ber of patients with CSHB by the total numbers ofHB (67) LC (77) CSHB (49) P-value
18/49 23/54 8/41 0.031
.1 ± 12.2* 50.7 ± 13.4* 44.2 ± 11.8 <0.001
3.1 ± 2.9 22.5 ± 3.3 22.9 ± 3.3 0.237
.5 ± 105.2* 76.6 ± 110.8* 423.5 ± 194.6* <0.001
6 ± 69* 65 ± 76* 156 ± 80* <0.001
2 ± 478* 82 ± 165* 309 ± 353* <0.001
0 ± 197* 83 ± 74* 242 ± 203* <0.001
7 ± 2235* 3072 ± 1468* 3477 ± 1370* <0.001
5 ± 0.86* 0.95 ± 0.73* 1.42 ± 0.79* <0.001
7 ± 0.87* 3.16 ± 1.67* 2.62 ± 1.49* <0.001
6 ± 0.45* 0.67 ± 0.45* 0.11 ± 0.15* <0.001
0 ± 0.68* 1.64 ± 0.71* 1.09 ± 0.87* <0.001
5 ± 0.38* 0.64 ± 0.30* 0.21 ± 0.16* <0.001
4 ± 0.24* 0.57 ± 0.25* 0.71 ± 0.33* <0.001
74 ± 17 80 ± 69 102 ± 77* 0.111
79 ± 0.85 5.45 ± 2.42* 4.86 ± 2.53 0.052
.2 ± 2.59 16.3 ± 5.2 23.5 ± 9.6 <0.001#
4 ± 315* 666 ± 267* 1320 ± 481* <0.001
6.9 ± 5.7 10.7 ± 7.0 24.7 ± 9.1 <0.001#
0/67 7/70 27/22 <0.001#
ere hepatitis B; Cr, creatinine; PT, prothrombin time.
ps. *P < 0.05 vs. the control group.
Figure 1 Correlation analysis between serum PAF-AH and TBIL (A, B) and TBA (C, D) in patients with hepatitis B (A, C) and in healthy
controls (B, D). Serum PAF-AH, TBIL, and TBA were measured by spectrophotometric assays in 152 healthy patients and 216 patients diagnosed
with hepatitis B. The Spearman correlation coefficients between these variables were determined as shown on the plots. No significant correlation
was detected between PAF-AH activity and TBA in healthy controls, but TBIL levels correlated positively with PAF-AH activities in both healthy
controls and hepatitis B–positive patients. TBA also correlated positively with PAF-AH in hepatitis B–positive patients.
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characteristics and differences in measurements for vari-
ables among the four groups are listed in Table 2. Patients
with the highest values of PAF-AH (group 1) had higher
MELD scores, incidence of CSHB, and mortality than pa-
tients with the lowest values of PAF-AH (group 4) (20.7 ±
9.9 vs. 7.0 ± 5.5, 35/19 vs. 1/53, and 17/37 vs. 1/53, re-
spectively; all P < 0.05).
ROC curve analysis was applied to estimate the ability
of PAF-AH activity and the MELD score to predict CSHB
in patients with hepatitis B (Figure 2, Table 3). The AUCs
of PAF-AH activity and the MELD score were 0.881 (95%
confidence interval (CI): 0.824–0.937, P < 0.001) and 0.921
(95% CI: 0.879–0.962, P < 0.001), respectively. When PAF-
AH and the MELD score were combined, the AUC was
0.951 (95% CI: 0.919–0.982, P < 0.001).Further ROC curve analysis was performed to estimate
the ability of PAF-AH activity and the MELD score to pre-
dict mortality in patients with hepatitis B (Figure 3,
Table 3). The AUCs of PAF-AH activity and the MELD
score were 0.757 (95% CI: 0.677–0.837, P < 0.001) and
0.883 (95% CI: 0.814–0.952, P < 0.001), respectively. When
PAF-AH and MELD were combined, the AUC was 0.882
(95% CI: 0.815–0.952, P < 0.001).
Gender, LDL-c, TBIL, the MELD score, and PAF-AH
were found to be associated with the prevalence of CSHB
(P = 0.016, 0.038, <0.001, 0.007, and <0.001, respectively) by
stepwise regression in which variables were selected from
age, gender, PAF-AH, ALT, AST, TBIL, ChE, TG, Tch,
LDL-c, HDL-c, apoAI, apoB, and TBA. Further multivariate
logistic regression analysis following adjustment for gender,
LDL-c, and TBIL showed that PAF-AH activity and the
Table 2 Clinical characteristics of patients with hepatitis B according to serum PAF-AH percentiles
Variable Group 1 Group 2 Group 3 Group 4 P-value
PAF-AH (U/L) >1053 709-1053 477-708 < 477
Female/male 14/40 13/40 25/30 18/36 0.077
Age (year) 44.6 ± 12.4 42.3 ± 12.5 45.1 ± 13.6 45.9 ± 16.1 0.574
BMI (kg/m2) 22.8 ± 3.6 22.8 ± 2.5 22.7 ± 2.3 23.0 ± 3.5 0.248
TBIL (μmol/L) 337.4 ± 206.9 139.1 ± 161.9 85.6 ± 148.3 59.1 ± 137.2 <0.001
TBA (μmol/L) 151 ± 79 110 ± 99 51 ± 56 37 ± 59 <0.001
ALT (U/L) 365 ± 456 507 ± 699 333 ± 454 243 ± 374 0.067
AST (U/L) 276 ± 264 223 ± 280 174 ± 201 121 ± 150 <0.001
ChE (U/L) 3766 ± 1905 4400 ± 2631 5000 ± 2716 5470 ± 2436 0.003
TG (mmol/L) 1.68 ± 0.94 1.35 ± 0.90 1.19 ± 0.59 1.04 ± 0.89 <0.001
Tch (mmol/L) 3.11 ± 1.48 3.51 ± 1.76 3.37 ± 1.23 2.94 ± 0.90 0.147
HDL-c (mmol/L) 0.22 ± 0.37 0.54 ± 0.49 0.69 ± 0.43 0.83 ± 0.44 <0.001
LDL-c (mmol/L) 1.28 ± 0.97 1.73 ± 0.91 1.80 ± 0.70 1.53 ± 0.57 0.005
ApoAI (g/L) 0.30 ± 0.27 0.60 ± 0.35 0.79 ± 0.40 0.85 ± 0.37 <0.001
ApoB (g/L) 0.82 ± 0.34 0.73 ± 0.31 0.67 ± 0.21 0.53 ± 0.16 <0.001
Cr (μmol/L) 89 ± 69 87 ± 84 94 ± 104 70 ± 13 0.323
Glu (mmol/L) 4.49 ± 1.84 5.67 ± 2.87 5.16 ± 1.57 4.86 ± 1.97 0.015
PT (s) 20.5 ± 9.4 17.2 ± 7.6 13.8 ± 3.9 13.9 ± 4.3 <0.001
MELD score 20.7 ± 9.9 14.0 ± 9.1 10.1 ± 8.2 7.0 ± 5.5 <0.001
Mortality (yes/no) 17/37 10/43 6/49 1/53 <0.001
CSHB (yes/no) 35/19 8/45 5/50 1/53 <0.001
Figure 2 ROC curve analysis for predicting CSHB in hepatitis
B–positive patients by serum PAF-AH and the MELD score.
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with odds ratios of 1.003 (95% CI: 1.002–1.005, P < 0.001)
for PAF-AH and 1.152 (95% CI: 1.037–1.279, P = 0.011) for
the MELD score.
Discussion
PAF is a potent inflammatory lipid mediator that, by bind-
ing to a high-affinity G-protein–linked receptor, can be ac-
tivated to exert diverse actions including stimulating
secretion and aggregation of platelets, initiating neutrophil
and macrophage chemotaxis, and inducing release ofTable 3 Cutoff values, sensitivity, and specificity of serum
PAF-AH and the MELD score in predicting CSHB and
mortality in hepatitis B patients
Cutoff values Sensitivity (%) Specificity (%)
Prediction of CSHB
PAF-AH (U/L) 910 81.6 82.2
MELD score 16.7 87.8 90.2
PAF-AH +MELD score 89.8 89.0
Prediction of mortality
PAF-AH (U/L) 799 76.5 66.5
MELD score 22.6 70.5 94.9
PAF-AH +MELD score 70.6 94.9
Figure 3 ROC curve analysis for predicting mortality in
hepatitis B–positive patients by serum PAF-AH and the
MELD score.
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proteolytic enzymes, and thus may be involved in the de-
velopment of circulation disorders and inflammation [18].
PAF accumulation has been implicated in pathological
processes and diseases including inflammation, endotoxin
shock, acute pancreatitis, and cardiovascular disease. PAF
is also involved in acute liver damage, cirrhosis, severe
hepatitis, and ischemia-reperfusion–induced liver injury
[19,20]. As a major mediator of PAF inactivation, PAF-AH
plays a crucial role in the regulation of serum PAF levels
and in reducing PAF-induced damage [8,21-23]. In experi-
mental models of acetaminophen-induced liver injury in
rats, PAF activities increased significantly between 24 and
32 h after acetaminophen administration, along with in-
creases in other biochemical indexes (ALT, AST). The
PAF-AH activity peaked between 72 and 96 h after acet-
aminophen treatment [24], indicating that PAF plays an
important role in acetaminophen-induced liver injury and
subsequent liver tissue repair, while PAF-AH can increase
liver recovery and reduce liver damage [25,26].
The pathological mechanism of hepatitis B is complex,
and patients’ symptoms are often complicated by intestinal
endotoxemia, the incidence of which can reach 80%–100%
in severe hepatitis cases [27]. Lipopolysaccharide (LPS) is
the major chemical endotoxin capable of stimulating PAF
and PAF-AH secretion from monocytes and macrophages.
Kupffer cells, specialized macrophages located in the liver,
account for 80%–90% of the total monocytes and macro-
phages in the body. Kupffer cells are the primary media-
tors of endotoxin clearance and detoxification in the liver.
By injecting bacterial LPS into the rat mesenteric vein,Howard et al. [28] observed a 20-fold increase in the
PAF-AH mRNA level in Kupffer cells and a 2-fold in-
crease in serum PAF-AH activity after 24 h. Svetlov et al.
[29] reported that cultured primary Kupffer cells could
express more PAF-AH mRNA than hepatocytes and
had a 20–25-fold higher PAF-AH secretion rate than
hepatocytes, indicating that Kupffer cells may be the
main source of PAF-AH during liver damage.
We found that the activity of circulating PAF-AH in pa-
tients diagnosed with hepatitis B was positively correlated
with TBIL, TBA, ALT, AST, TG, and apoB, negatively cor-
related with ChE, HDL-c, and apoAI, and not correlated
with Glu, BMI, Tch, and LDL-c. However, the PAF-AH ac-
tivity in healthy controls was positively correlated with
TBIL, ALT, TG, Tch, LDL-c, and apoB, negatively corre-
lated with HDL-c, and not correlated with Glu, BMI, TBA,
AST, and apoAI. The differences in correlations between
hepatitis patients and controls, especially in the correl-
ation of PAF-AH with lipids and bile acids, could be ex-
plained by a change in the source of PAF-AH during the
development of hepatitis. PAF-AH can be classified into
intracellular types I and II and the plasma type [3]. Plasma
PAF-AH exists in the blood and is predominantly pro-
duced by monocytes, macrophages, T lymphocytes, mast
cells, and hepatocytes [30-32]. Under normal conditions,
the main source of circulating PAF-AH is hematopoietic
cells [31], and the main source of PAF-AH in bile juice is
hepatocytes [29]. However, during hepatitis bile excretion
disorder, the retention of bile components such as bile
acid can cause the retention of hepatocyte-secreted PAF-
AH [33,34]. This relationship could explain the association
between serum PAF-AH activities and the TBIL and TBA
levels in hepatitis. Another potential factor is the impact
of liver damage on Kupffer cell PAF-AH secretion, leading
to an increase in PAF-AH during hepatitis. Circulating
PAF-AH mainly exists in complexes with lipoprotein par-
ticles [35]. During hepatitis, however, liver damage causes
dysfunction in the synthesis of cholesterol and other lipids
[36], resulting in the altered correlation between PAF-AH
and blood lipids we observed. These findings indicate that
serum PAF-AH may be involved in oxidative stress and in-
flammation of the liver.
We also found that serum PAF-AH activities in patients
with various stages of hepatitis B were significantly higher
than those in healthy controls, and serum PAF-AH activity
was significantly positively correlated with TBIL. The great-
est elevation in serum PAF-AH was observed in patients di-
agnosed with CSHB, suggesting that the PAF-AH activity is
involved in pathological liver damage, and that the detec-
tion of PAF-AH may serve as a surrogate marker for hep-
atic inflammatory activity, allowing disease progress and
prognosis to be monitored. Similar to our study, the study
of Ma et al. found that among CSHB patients, serum PAF
activities were significantly higher in the death group than
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prognosis of CSHB, and thus can be used as a prognostic
factor in CSHB [37]. However, Guerra et al. found that
HCV-infected patients showed a significant decrease in
PAF-AH activity, and PAF-AH activity recovered only in
patients who cleared HCV after antiviral treatment [38].
Most of the circulating HCV is associated with VLDL and
LDL, and the circulating HCV lipoprotein complexes may
reduce the amount of free LDL available for PAF-AH activ-
ity. Since HBV does not circulate in blood bound to LDL,
HBV-infected patients did not show any reduction in PAF-
AH activity [38,39].
In this study, we show that serum PAF-AH may be used
for predicting CSHB and 3-month mortality in HBV-
infected patients. We evaluated the predictive power of
PAF-AH and the MELD score by ROC curve analysis. The
MELD score is a prospectively developed and validated
scale for the severity of end-stage liver disease that uses
the quantitative, objective values of serum TBIL, serum
creatinine, and INR of prothrombin time to predict patient
mortality in patients with advanced liver disease [16,40].
Mao et al.’s study reported that the MELD score was re-
lated to the prognosis of patients with HBV-related acute-
on-chronic liver failure [41]. We found that although the
AUC of PAF-AH was lower than the AUC of the MELD
score for predicting CSHB, the AUC of PAF-AH com-
bined with MELD score was higher than that of PAF-AH
or the MELD score alone. This finding showed that com-
bining PAF-AH with the MELD score further added to
predictive power for CSHB. Multivariate logistic regres-
sion analysis showed that PAF-AH activity and the MELD
score were independent factors predicting CSHB. We also
found an association between PAF-AH and mortality in
HBV-infected patients. The AUC of PAF-AH was lower
than AUC of the MELD score for predicting mortality,
and the AUC of PAF-AH combined with the MELD score
was similar to that of the MELD score alone. Although
this result shows a lower predictive power of PAF-AH
than of the MELD score for mortality, PAF-AH activity is
an easier and more convenient measurement than the
MELD score. However, a potential limitation in our study
was that we did not consider the influence of drugs taken
before admission that may modulate PAF-AH activity.
In summary, the PAF-AH activities of patients with
CSHB were significantly higher than those of patients
with AHB, CHB, or LC, and higher PAF-AH activities
were associated with a higher prevalence of CSHB.
Spearman correlation showed that PAF-AH activity cor-
related positively with TBIL, TBA, ALT, AST, TG, and
apoB and negatively with ChE, HDL-c, and apoAI in pa-
tients with hepatitis B. Moreover, serum PAF-AH may
be used for predicting CSHB and mortality in patients
with hepatitis B, and PAF-AH activity was an independ-
ent factor predicting CSHB.Abbreviations
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